Research programme: farnesoid-X-activated receptor agonists - Metacrine

Alternative Names: M 480; MET 409

Latest Information Update: 22 Nov 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Metacrine
Class Antifibrotics; Hepatoprotectants; Small molecules
Mechanism of Action Farnesoid X-activated receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

17 Apr 2018 Metacrine plans a first-in-human clinical trial of MET 409 by mid-2018
20 Oct 2017 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis and Fibrosis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
10 Oct 2017 Preclinical trials in Fibrosis in USA (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.